Karyopharm Therapeutics (STU:25K) Change In Payables And Accrued Expense : €4.2 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Karyopharm Therapeutics Change In Payables And Accrued Expense?

Karyopharm Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was €-2.7 Mil. It means Karyopharm Therapeutics's Accounts Payable & Accrued Expense declined by €2.7 Mil from Dec. 2023 to Mar. 2024 .

Karyopharm Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €4.0 Mil. It means Karyopharm Therapeutics's Accounts Payable & Accrued Expense increased by €4.0 Mil from Dec. 2022 to Dec. 2023 .

Karyopharm Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Karyopharm Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Change In Payables And Accrued Expense Chart

Karyopharm Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

4.69

12.85

11.61

-7.90

3.99

Karyopharm Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-2.94	-1.32	1.84	6.38	-2.72

Karyopharm Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.2 Mil.

Karyopharm Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Karyopharm Therapeutics (STU:25K) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (STU:25K) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

KPTI:USA

Address

85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459

Website

https://www.karyopharm.com

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Karyopharm Therapeutics (STU:25K) Headlines

No Headlines